Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
“Genes, Chromosomes and “Genes, Chromosomes and
Cancer”
Carlos A. Tirado, Ph.D., FACMG
• 1890, David von Hansemann speculated that the abnormal mitotic figures in cancer biopsies were important to the origin and that the abnormal mitotic figures in cancer biopsies were important to the origin and development of maligancies.
• In 1914, Theodor Boveri published a systematic somatic mutation theory of cancer stating that chromosome abnormalities were responsible for cellular cancer stating that chromosome abnormalities were responsible for cellular changes that caused normal cells to become malignant.
Chronic Myeloid Leukemia
NOWELL 1960
Molecular modification
in Ph chromosomeJanet Rowley in 1974
22
9
Ph
9+
bcr
abl
bcr-
abl
ABL1
BCR ABL1/
BCR
• The catalytic domain of ABL1 is fused to a domain on BCR that mediates constitutive oligomerization of the fusion protein in the absence of physiological activating signals, thereby promoting aberrant tyrosine kinasethereby promoting aberrant tyrosine kinaseactivity.
JAK2JAK2BCRBCR ABL1ABL1
MYCMYC
BCL2BCL2
Where does it go wrong?
G1
TP53
M
GoG2
DNA
Repair Tumor
OncogenesOncogenesOncogenesOncogenes
GoTP53
Rb1GoGo
G1G1
Rb
S
Repair
genesTumor
Suppressor
GenesSynthesis
DNA replication
Rb
-P04Cyclin
B-P04
Cyclin D
Rb
+P04:
Cyclin
A
B
TP53
+P04:
Free E2
Cyclin E
CYCLIN D1: CCND1 (11q13)
• It shows amplification in Burkitt’s• It shows amplification in Burkitt’s
lymphoma, breast cancer.
• CCND1 would also cooperate to
activate RAS and MYC. activate RAS and MYC.
CYCLIN D1: CCND1 (11q13)
• t(11;14) (q13;q32) is a recurrent
abnormality detected in 50-70% mantle cell
lymphoma cases & 10-20% plasma cell
myeloma (PCM).
• According to the literature, PCM patients
with the t(11;14)(q13;q32) are characterized with the t(11;14)(q13;q32) are characterized
by cyclin D1 up-regulation and a
lymphoplasmacytic morphology.
Mantle cell lymphoma
• No fusion protein, but promoter exchange.• No fusion protein, but promoter exchange.
• The immunoglobulin gene enhancer
stimulates the expression of BCL1
(CCND1).
• Oncogenesis: Overexpression of BCL1 • Oncogenesis: Overexpression of BCL1
accelerates passage through the G1 phase.
Loss of tumor suppressor genes:
1963: Retinoblastoma1963: Retinoblastoma
Cavenee et alCavenee et al: Deletion of a : Deletion of a
DD--group chromosomegroup chromosome
Deletion 13q
• Plasma cell myeloma
• B Chronic lymphocytic leukemia
• Non Hodgkin’s lymphomas
• Acute Myeloid leukemia
• Myelodysplastic syndromes (Refractory
anemia)
45,X,-Y,add(3)(p21),r(7)?(p22q32),add(8)(q24)x2,
add(10)(q24),-13,+17,dic(1;21)(q11;q22)[8]/
46,XX[12]
t(4;14)(p16;q32)
Poor prognosis
t(14;16)(q32;q23)
Poor prognosis
Plasma Cell Myeloma
• 13 q deletions:
Adverse/intermediate Adverse/intermediate
prognosis
• t(11;14): Intermediate
prognosis
• t(4;14): Adverse prognosis
• t(14;16): Adverse prognosis
• +1q or amplification of • +1q or amplification of
CKS1B: High standard risk in
PCM
Chromothripsis
Chromosome catastrophes involve
replication mechanisms generating complex genomic rearrangements.
Poor outcome in PCM.
Cell 148, January 2012:29-32Cell 148, January 2012:29-32
CKS1B in Plasma cell myeloma (PCM)
• CKS1B amplification is seen in monoclonal
gammopahy of undetermined signficance and PCM.gammopahy of undetermined signficance and PCM.
• British Journal of Haematology (2006) Vol 134,
Issue 6: 613-615 .
• A specific role for increased expression of CKS1B,
as a consequence of 1q21 copy number gain has
been postulated as both pathogenic as well as a been postulated as both pathogenic as well as a
powerful clinical prognostic factor in PCM.
• Leukemia (2006) 20: 2034-2040.
Deletion 13q in CLL
• ~ly 50% of CLL cases.
nuc ish (D12Z3x2,D13S319x0,D13S1020x2)[200/200]
CLL• Trisomy 12 : Adverse/Intermediate prognosis. It
can be associated with poor survival.can be associated with poor survival.
• Del(11)(q22-q23): Disease progression and
decreased survival.
• Del(13)(q14): Favorable. The common deleted
region is around 1.6 cm telomeric to the Rbregion is around 1.6 cm telomeric to the Rb
gene.
• Del(17)(p13): Shorter survival & treatment
failure.
Deletion 13q in CLL
• CLL carrying 70% of 13q deleted nuclei with
deletions not comprising the RB1 locus are deletions not comprising the RB1 locus are
characterized by a particular long time to treatment.
• CLL with 13q deletions in < 70% of nuclei
involving the RB1 locus or carrying 13q deletions
(mono allelic or bi allelic) in > 70% with or without
the RB1 are associated with a shorter time to the RB1 are associated with a shorter time to
treatment (Intermediate to unfavorable prognosis).
• Genes, Chromosomes & Cancer 50: 633-643 (2011)
miRNAs on 13q14.3 and 11q22
• 13q14.3 & 11q22-23 are cancer associated • 13q14.3 & 11q22-23 are cancer associated
genomic regions (CAGR) frequently deleted in
CLL harbors the micro-RNAS clusters
miR-15a/miR-16-1 in 13q
miR34b/miR34c in 11q
miR-9 and miR-223 (potential importance as miR-9 and miR-223 (potential importance as
biomarkers in recurrent ovarian cancer)
miR-15a & miR-16-1
• Downregulate BCL2 in a normal conditions with • Downregulate BCL2 in a normal conditions with
repression of its expression & promote apoptosis.
• Deletions or a downregulation of these mi-RNAs
would allow an overexpression of
BCL-2 and loss of APOPTOSIS.
Therefore these mi-RNAs could be promissingTherefore these mi-RNAs could be promissing
antisense BCL-2 molecules able to suppress the
BCL-2 overexpression in CLL & B-cell neoplasias.
miR-9, a MYC/MYCN-activated microRNA,
regulates E-cadherin and cancer metastasis
• It is upregulated in breast cancer cells, directly • It is upregulated in breast cancer cells, directly
targets CDH1, the E-cadherin-encoding messenger
RNA, leading to increased tumor angiogenesis.
• Significantly, in human cancers, miR-9 levels
correlate with MYCN amplification, tumor grade
and metastatic status.and metastatic status.
• Inhibiting miR-9 in highly malignant cells
inhibits metastasis formation.
• Nature Cell Biology (21 February 2010)
SF3B1 and other Novel Cancer Genes
in CLL
• SF3B1, which functions at the catalytic core of the • SF3B1, which functions at the catalytic core of the
splicesome, was the second most frequently mutated
gene (15% cases).
• TP53 (15%), ATM (9%), MYD88 (3p22) [10%] &
NOTCH1 (9q34.3) [4%]. Others were ZMYM3,
MAPK1, FBXW7, and DDX3X. MAPK1, FBXW7, and DDX3X.
• The New England Journal of Medicine (2011) 365(26): 2497-2506
SF3B1 in CLL
• SFB31 (2q33.1) mutations in CLL occur
primarily with deletions 11q involving the primarily with deletions 11q involving the
ATM gene: Poor prognosis.
• Mutations in SF3B1 had alterations in pre-
messenger RNA (mRNA) splicing of a
narrow spectrum of transcripts derived from
genes involved in cancer related processes, genes involved in cancer related processes,
including cell cycle control, angiogenesis and
apoptosis. • The New England Journal of Medicine 2011
CLL
• Mutations in NOTCH1 and FBXW7 were
associated with trisomy 12.
• NOTCH1 mutations were consistently associated
with unmutated IGHV.
• MYD88 mutations were present in samples that
were heterozygous for del (13q) and mutated IGHV
status.
• Splicing function in CLL is altered as a result of
mutations in SF3B1 rather than deletion 11q.
• The New England Journal of Medicine (2011) 365(26): 2497-2506
“Multiple-hit hypothesis”
Normal tissue “Normal” tissue
(hemizygous BRCA1
deletion)
Hyperproliferative cells
(homozygous BRCA1
deletion)
Tumor suppressor
loss (ie. TP53)
Atypical
hyperplasiaInvasive cancer
loss (ie. TP53)
Oncogene activation
(ie. MYC amplification)
GENES INVOLVED IN
CANCER
• ONCOGENES:
MYC (8q24), ABL1 (9q34)
• TUMOR SUPPRESSOR GENES:
RB1(13q14), TP53(17p13),
BRCA1(17q21), BRCA2(13q12)
• DNA REPAIR GENES: MSH2(2p21-22), PMS2 (3p21).PMS2 (3p21).
• APOPTOSIS REGULATING GENES:BCL2 (18q21), TP53(17p13).
• CELL CYCLE REGULATORS: CDKN2 (9p21), MDM2(12q14)
CANCER CELLS SHOW :
A.- Loss of differentiation
B.- Increased invasiveness
C.- Decreased drug sensitivity
D.- Karyotypic alterations: Whole D.- Karyotypic alterations: Whole chromosome gains and loss, ploidy changes.
Fanconi anemia (FA)
• A chromosome instability syndrome with progressive bone marrow failure and an increased risk of cancers.risk of cancers.
• Cases of MDS and AML arising in patients with FA appear to be preceded by isolated focal gains or cryptic rearrangements of 3q26 that cause overexpression of the EVI1 (ecotropic viral integration site 1) gene.
• This early genetic event may have a role in the • This early genetic event may have a role in the development of cancers that result from a constitutional imbalance between genotoxic stress and DNA repair.
Fanconi anemia
• Spontaneous
chromatid/chromosome chromatid/chromosome
breaks, triradials,
quadriradials with
mitomycin C (MMC) &
diepoxybutane (DEB).
• Abnormalities found in
MDS or AML:MDS or AML:
• -5/del(5q), and -7/del(7q),
in 10 % of cases
.
Fanconi anemia (FA)
Cryptic inversion
• inv(2)(p22-p21p23) in 6.7% of Japanese
patients with non–small-cell lung patients with non–small-cell lung
cancer, will result in the formation of a
fusion gene comprising portions of
EML4 and the gene encoding the ALK
receptor tyrosine kinase.
Juvenile myelomonoytic
leukemia (JMML)
• Association of JMML and NF1 (200-500x).• Association of JMML and NF1 (200-500x).
• Occasionally infants with Noonan syndrome develop a JMML-like disorder.
• In 35% of Noonan patients, a germline mutation in the PTPN11 (12q24) : The gene encoding the protein tyrosine phosphatase (SPH2).protein tyrosine phosphatase (SPH2).
• NRAS, KRAS and NF1.
Nomenclature - some rules
• Use standard abbreviations (del, inv, dup, • Use standard abbreviations (del, inv, dup,
etc.)
• List chromosomes in order from X, Y,
1,2,…22
• If multiple abnormalities, keep in same • If multiple abnormalities, keep in same
order, but list numerical before structural
abnormalities (eg. 47,XY,+21,del(21)
ISCN (Nomenclature)
46, XY,t(9;22)(q34;q11)[12]/
48,idem,+8,+12[8]
46,XX,add(19)(p13)
46,XX,der(19)t(19;?)(p13;?) 46,XX,der(19)t(19;?)(p13;?)
46,XX,del(6)(q13q23)[8]/46,XX[12]
Types of probes:
Centromeric WCP probes
Locus
specific
Dual Color, Break Apart
Rearrangement Probes
• If normal:
46,XY[20].nuc ish (5’MLL,3’MLL)x2
(5’MLL con 3’MLLx2)[200]
• If Abnormal:
nuc ish (MLLx2)(5’MLL sep nuc ish (MLLx2)(5’MLL sep
3’MLLx1)[196/200]
TXL3 on 5q35
RGF
46,XY[20].ish (TXL3x2)(5’TLX3 sep
3’TLX3x1)[20]
In T-ALL with t(5;14)(q35;q32)
Dual Color, Dual Fusion
Translocation Probes
LSI BCR/ABL
t(9;22) in CML
RGFF pattern
RGFF
46,XY,t(9;22)(q34;q11.2)[20].nuc ish
(ABL1,BCR)x3,(ABL1 con
BCRx2)[179/200]
Myelodysplastic syndromes • Clinically heterogeneous disorders for which
treatments are tailored to the predicted prognosis for each patient.each patient.
• Current prognostic scoring systems consider karyotypic abnormalities and certain clinical features to stratify patients with MDS into risk groups.
• > ½ of patients with MDS: Normal karyotype.
• An understanding of the clinical effects of mutations • An understanding of the clinical effects of mutations in various genes could improve the prediction of prognosis for patients with MDS and inform the selection of specific therapies.
Recurring chromosomal abnormalites and
their frequency in MDS at diagnosis
Unbalanced
+8+8
-7/del7q 10% 50% therapy related
-5/del5q 10% 40% therapy related
del(20q) 5-8%
-Y 5%
i(17q) or (i17p) 3-5%
Del(11q) 3%
Del(12p) or t(12p) 3%
Del(9) 1-2%
Idic(X)(q13) 1-2%
Recurring chromosomal abnormalites and
their frequency in MDS at diagnosis
Balanced
t(11;16)(q23;p13.3) 3% (therapy related)t(11;16)(q23;p13.3) 3% (therapy related)
t(3;21)(q26.2;q22.1) 2% (therapy related)
t(1;3)(p36.3;q21.2) 1%
t(2;11)(p21;q23) 1%
inv(3)(q21q26.2) 1%
t(6;9)(p23;q34) 1%
Myeloid malignancies
recurrent abnormalities
• MDS, MPD, • MDS, MPD,
AML
• Prognostic value
• (5q-, -7, 7q-, +8,)
del(5q)
del(5)(q13q33)
del(7)(q22) or
monosomy 7
t(3;21)(q26;q22)
EVI1 (Ecotropic Viral Integration Site 1 (EVI1) on 3q26
inv(3)(q21q26.2)
t-MDS and t-AML
5q- Syndrome
• Severe macrocytic anemia
• Normal or elevated platelet counts, normal or • Normal or elevated platelet counts, normal or
reduced neutrophil counts.
• Defect in erythroid differentiation.
• Hypolobulated micromegakaryocytes.
• Tendency to AML but slower than other forms of
MDS.
• Response to Revlimid
• ~ 1.5 Mb : 40 genes
• EGR1 gene
• PDGFRB
• RPS14 encodes a protein that is a component
of the 40S subunit of the ribosome.of the 40S subunit of the ribosome.
• ? Function but its deficiency blocks
preribosomal RNA processing and the
polymer formation of the 40S
• A link between the 5q- syndrome (Deletion
of one allele of RPS14) & congenital bone
marrow failure syndromes (Diamond-Black
Anemia) caused by the heritable mutation of
other ribosome-associated proteins.
Deletion 11qnuc ish(MLLx1)[20/200]
• Deletion of 11q23 are observed in treatment • Deletion of 11q23 are observed in treatment
related MDS (RARS, RAEB-1)/MPN
(CMML, JMML), AML, ALL,
biphenotypic leukemias.
• Therapy with topoisomerase II inhibitors is
associated with balanced abnormalities:
MLL rearrangements.
Myelodysplastic syndromes
• Mutations of TET2, RUNX1, TP53, NRAS, JAK2 ,
ETV6, PTPN11, BRAF, PTEN & CDKN2A have
been reported to be associated with MDS.
• Mutations in TP53, EZH2, ETV6, RUNX1 and
ASXL1 are predictors of poor overall survival,
independently of established risk factors.
• The mutated genes most strongly associated with a
specific karyotype group were TET2 and TP53.
• N Eng J Med June 29, 2011
Schanz et al. Journal of Clinical
Oncology (2012)
The 17p- chromosome• Loss of TP53 gene.
• 10-15% of follicle centre cell lymphoma • 10-15% of follicle centre cell lymphoma
(FCCL) & mantle cell lymphoma (MCL).
• Minority of marginal zone B-cell
lymphomas may be associated with 17p
deletion deletion
• Plasma Cell Myeloma and CLL.
• Poor prognosis in low grade lymphomas.
i(17q) in myeloid malignancies
dic(17;20) in myeloid malignancies
Case A1
• 57 year old patient with a history of stage • 57 year old patient with a history of stage IV diffuse large B-cell lymphoma status post 6 cycles of combination chemotherapy six years ago.
• In August 2002 presented with enlarged lymph nodes, anemia and leukocytosis.lymph nodes, anemia and leukocytosis.
• Peripheral blood smear from patient showing • Peripheral blood smear from patient showing
anemia, leukocytosis with increased granulocytes
and precursors. No increase in circulating blasts,
basophils, or platelet abnormalities was observed.
• Patient bone marrow showing hypercellularity
with marked myeloid hyperplasia and mild with marked myeloid hyperplasia and mild
eosinophilia (13%), with no increase in blasts.
BCR/ABL probe
RRGGG pattern VARIANT signal pattern
46,XY,t(4;22)(q12;q11.2)
CASE A1: t(4;22)(q12;q11.2)
BCR with Platelet derived growth factor receptor alpha
GEF Ser-Thr
tyrosine
177 Grb-2
site
CDC BCR TK1 TK2Olig
BCR exons 1-17
(1005 AA)
GEF
dbl-l
Ser-Thr
kinase
CDC
24
BCR
PHTK1 TK2
PDGFRA exons 12-23
(520 AA)
Diagrammatic representation of BCR and PDGFRA functional
domains
of the predicted approximately 4.6 kb full-length mRNA fusion
transcript
which is expected to encode a 1525 aa 169 kDa protein
Myeloid & lymphoid neoplasms with
eosinophilia and abnormalities of PDGFRA
rearrangement (MPN) :Deletion at 4q12
FIP1L1/PDGFRA FUSION GEN
Deletion at 4q12
Dysregulates tyrosine kinase activity
& transforms hematopoietic
CellsCells
BUT it is inhibited
by GLEEVEC
• Presentation as CEL (chronic
FIP1L1 and PDGFRA fusion
• Presentation as CEL (chronic
eosinophilia leukemia) but can also
present as AML, precursor T-
lymphoblastic lymphoma (T-LBL) .
• Rare cases of fusion of BCR with • Rare cases of fusion of BCR with
PDGRA resulting from a
t(4;22)(q12;q11).
Myeloid neoplasms with PDGFRB
rearrangement :
5q33
Chronic myelomonocytic leukemia (CMML)
with eosinophilia
t(5;12)(q31-q33;q24) KIAA15009-PDGRB
t(5;17)(q33;p11.2) SPECC1-PDFGRB
Myeloid neoplasms with FGFR1Myeloid neoplasms with FGFR1
rearrangement :
8p11.2
Platelet derived growth factor receptor beta:
PDGFRB (5q32-q33)
• Rearrangements of
the PDGFRB gene
can result from a
gene fusion to one of
as many as 15
different known different known
partner genes.
Myeloproliferative Neoplasms:
Chronic myelogenous leukemia, BCR-
ABL1 positive
Distinct forms of BCR-ABL1 from
alternative chromosome 22
breakpoints
• Deletion of any part of the BCR or ABL1 gene on the derivative chromosome 9 is a poor prognostic marker that derivative chromosome 9 is a poor prognostic marker that indicates rapid disease progression in chronic myeloid leukemia [Cancer Genet Cytogenetics: 2006 Apr 1;166(1):65-73].
• All the patients with BCR deletion, except for one, had a concomitant ABL1 deletion, suggesting that BCR deletion occurs in conjunction with ABL1 deletion. occurs in conjunction with ABL1 deletion.
• Deletion of any of the BCR or ABL1 genes on derivative chromosome 9 was associated with poor prognosis in CML.
22
9
Ph
der 9
der 99
22Ph
Myeloproliferative Neoplasms
Chronic neutrophilic leukemia: +8, +9,+21, Chronic neutrophilic leukemia: +8, +9,+21, del(20q),del(11q), del(12p)
Polycythaemia vera: del(20q)
Primary myelofibrosis: del(20q), partial trisomy 1q, del(13q), der(1;6)(q21-q23;p21.3)
Essential thrombocythaemia: +8, 9q Essential thrombocythaemia: +8, 9q rearrangements, del(20q) and del(5q)
Myeloproliferative neoplasms:
del(20q)
JAK2 Mutations in
Myeloproliferative
Neoplasms:
A valine to phenylalanine A valine to phenylalanine
substitution at position 617
(V617F) in the pseudokinase
kinase-like domain of JAK2.
Deregulation of the kinase activity, and
thus to constitutive tyrosine
phosphorylation activity.phosphorylation activity.
The JAK2 allele burden decreases
with successful therapy, disappears
in some patients, and reappears
during relapse.
V617F mutation
PV (~ 95%), essential thrombocythemia & idiopathic myelofibrosis idiopathic myelofibrosis
~ 20% of Ph-negative (ATYPICAL CML)
Minority of hypereosinophilic syndrome
> than 10% of CMML
~ 15% of (Acute megakaryoblastic leukemia) ~ 15% of (Acute megakaryoblastic leukemia)
& 1/5 patients with JMML.
Activating mutations of MPL (1p34)
exon 10
• Idiopathic myelofibrosis (IMF) or essential
thrombocythemia (ET). thrombocythemia (ET).
• Mutations in the myeloproliferative leukemia gene (MPL)
exon 10:
W515L and W515K are associated with severe
anemia and have been detected in patients with ET
or MF but not in patients with PV. or MF but not in patients with PV.
• An inherited MPL mutation (S505N; exon 10) has also
been found in a Japanese pedigree with familial ET.
Exon 12 mutations
A2
• A 14-year-old Hispanic male presented with increasing • A 14-year-old Hispanic male presented with increasing
weakness and decreased appetite. Laboratory examination
revealed hyperleukocytosis (white blood cell count of
253,000×109/L), anemia (hemoglobin 3.3 g/L) and
thrombocytopenia (platelet count of 36,000×109/L).
BCR (green), ABL1 (red), WNL
46,XY,t(9;22)(p24;q13)[14]/46,XY[7]
9
22
der(22)
der(9)
DiGeorge
Probe
der9
der22
ARSA signal
der22
Normal 9der9
Normal 9der9
der 22
Normal 9
der 9
• Induce the dimerization or
Translocations of
JAK2
• Induce the dimerization or
oligomerization of JAK2 without ligand
binding, which also results in constitutive
activation of JAK2.
Primary structure of JAK1, JAK2, and JAK3 showing the
location of missense (▼) and insertion/deletion (▲) mutations
Mullighan C G et al. PNAS 2009;106:9414-9418
©2009 by National Academy of Sciences
R683S and R683G � JAK-STAT activation.
R867Q and D873N in JH1 also cause
JAK mutations in pediatric ALL patients
R867Q and D873N in JH1 also cause
enhanced kinase activity of JAK2� JAK-STAT
activation.
S798P in JAK3 and L624_R629>W, S646F
and V658F in JAK1.and V658F in JAK1.
PNAS (2009) Vol 106 no. 23 p.9414-18.
JAK2R683
JAK2 exon 16 mutations in 18% cases
of Down Syndrome with ALL
JAK2R683
Arginine 683 mainly point mutations,
Complex in-frame insertion and deletion
events proximal to R683
JAK2 constitutive activation and JAK2 constitutive activation and
cytokine-independent growth in vitro.
Br J Haematol. 2009 144(6): 930-932.
Deletion of IKZF1 (encoding the lymphoid
Pediatric BCR-ABL1-negative
ALL patients
Deletion of IKZF1 (encoding the lymphoid
transcription factor IKAROS) &
CDKN2A/CDKN2B.
A poor prognosis similar to BCR-ABL1-
positive ALL, raising the possibility of
activated tyrosine kinase signaling within this
leukemia subtype.
PNAS (2009) Vol 106 no. 23 p.9414-18.
Hyperdiploidy
>50 chromosomes
25.0%
Hypodiploidy
<45 chromosomes
1.0%Others
22.0%
BCR/ABL
t(9;22)
Common anomalies in ALL (pediatric)
Hyperdiploidy
(25%)
Hypodiploidy
(1%)
t(9;22)
(3%)
Others
(22%)
TEL/AML1
t(12;21)
22.0%
3.0%
MLL
rearrangements
8.0%HOX11L2
5q35
2.5%
LYL1
(25%)
t(12;21)
(22%)
(3%)
MLL
(8%)
MYC
t(8;14)
2.0%TCF3/PBX1
t(1;19)
5.0%
HOX11
10q24
0.7%
LYL1
19p13
1.5%
MLL-ENL
0.3%
TAL1
1p32
7.0%
(22%)
t(8;14)
(2%)MLL-ENL
(0.3%)
t(1;19)
(5%)
19p13 (1.5%)
1p32 (7%)
4 and 10
Hyperdiploidy: ALL
Hyperdiploidy in ALL
favorable prognosis
Bone MarrowBone Marrow
57 Chromosomes
ABNORMALITYABNORMALITY ADULTSADULTS CHILDRENCHILDREN
t(9;22)t(9;22) 3030--37%37% 22--6%6%
t(12;21)t(12;21) 00--3%3% 2020--25%25%
Abnormalities seen in >5% of adults and/or
children with ALL
t(12;21)t(12;21) 00--3%3% 2020--25%25%
AbnAbn(9p)(9p) 66--30%30% 77--11%11%
High High hyperdiploidyhyperdiploidy 22--11%11% 2323--26%26%
t(4;11)t(4;11) 33--7%7% 2%2%
Del(6q)Del(6q) 33--16%16% 66--9%9%Del(6q)Del(6q) 33--16%16% 66--9%9%
Del(7p/q)Del(7p/q) 66--11%11% 4%4%
+8+8 1010--12%12% 2%2%
Abn(12p)Abn(12p) 44--6%6% 77--9%9%
Low hyperdiploidyLow hyperdiploidy 1010--15%15% 1010--11%11%
ALL FISH requirements
B - lineage patients:B - lineage patients:
If very young: TEL/AML1
If older than 10 years:
BCR/ABL1 dual fusion and MLL
CEN 4 and 10 CEN 4 and 10
dup(21q) amplified (RUNX1)
• Acute lymphoblastic leukemia : B-lineage immunophenotype (mostly common or Pre-B), FAB L1/L2
Precursor B cell Acute Lymphoblastic
Leukemia
Unfavorable prognosis
– t(9;22)(q34;q11.2); (BCR/ABL) (e1a2)
– t(4;11)(q21;q23); (AF4/MLL)
– Hypodiploid
Intermediate prognosis
t(1;19)(q23;p13); (E2A/PBX1)t(1;19)(q23;p13); (E2A/PBX1)
Favorable prognosis
– t(12;21); (TEL-AML1)
– Hyperdiploid >50
AML FISH requirements
• If normal karyotype results:• If normal karyotype results:
CBFß inv(16)/t(16;16)
11q23: MLL
t(8;21): ETO/AML1t(8;21): ETO/AML1
5q-,7q-
AML with balanced rearrangements
AML with (8;21)(q22;q22);RUNX1-RUNXT1RUNXT1
AML with inv(16)(p13.1;q22);CBFB-MYH11
AML with (15;17)(q22;q12);PML-RARA
Variants
AML with (9;11)(p22;q23);MLLT3-MLLAML with (9;11)(p22;q23);MLLT3-MLL
Intermediate survival better than any other MLL rearrangement
AML with balanced rearrangements
AML with (6;9)(p23;q34); DEK-NUP214AML with (6;9)(p23;q34); DEK-NUP214
Anemia & thrombocytopenia. Poor prognosis
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2);RPN1-EVI1 :
Poor prognosisPoor prognosis
AML with (1;22)(p13;q13);RBM15-MKL1
Case A4
• WBC 11.1X109/L with 69% blasts. • WBC 11.1X109/L with 69% blasts.
• The bone marrow aspirate : Increased marrow
cellularity (90%).
• Cytochemistry demonstrated that the blasts were
positive for myeloperoxidase and negative for
non-specific esterasenon-specific esterase
• Flow cytometry: Aberrant population of • Flow cytometry: Aberrant population of
myeloblasts expressing CD45, CD34,
CD117, HLA-DR, MPO, CD13, CD33,
CD15, CD19 and CD56.
ETO/AML1 t(8;21)(q22;q22)ETO/AML1 t(8;21)(q22;q22)
2121
ETO on chrom 1
21
88
8
t(8;21)
8
Chr 1
Chr 21
der 8
Chr 21
Chr 8
Chr 21
P58 probe (1p36)
Chromosome 21 Chromosome 21Chromosome 1
Chromosome 1
AML with t(8;21)
• RUNX1 and RUNX1/RUNXT1 recognize the • RUNX1 and RUNX1/RUNXT1 recognize the
same binding sequence in the DNA, but the
hybrid RUNX1/RUNXT1 recruits additional
cofactors, mostly repressors, working as a
transcriptional repressor for the RUNX1 WT
target genes & ARREST MYELOID target genes & ARREST MYELOID
DIFFERENTIATION.
RUNX1/RUNXT1 recruits the NCoR/HD
Co-Repressor Complex to CBF
promoters
RUNX1T1RUNX1T1
RUNX1RUNX1
NCoRNCoR
HDHD
NO NO
TRANSCRIPTIONTRANSCRIPTION
Case A5
• By In January 2009, a 30-year-old man was
taken for urgent surgery due to bruising and taken for urgent surgery due to bruising and
ecchymoses in his lower extremities. A chest
computed tomography revealed a right atrial
mass.
• By
• By
Case A5
• By
Case A5
• By
• He was then treated with ATRA/ATO and local radiation therapy to all sites of disease.
• In September 2009, he had an MS relapse in a • In September 2009, he had an MS relapse in a supraclavicular mass.
• PET scan again showed multiple sites of disease in soft tissue, but bone marrow was normal.
• He is now being treated with ATRA/GO, but • He is now being treated with ATRA/GO, but response is yet to be determined.
Met1/FISH1
Case 2009
• By
• PML gene
Chromosomal rearrangements that
entail transcriptional repression: APL
• PML gene
Encodes a protein involved in tumor suppression & apoptosis.
• RARα gene
Encodes a protein
PML RARαααα
t(15;17)(q22;q21)
Encodes a protein involved in myeloid differentiation
PML/RARα Fusion Gene
• Interferes with the normal RARα function• Interferes with the normal RARα function
– Blocking the differentiation of promyelocytes(Maturation block): PML/RARA is a transcriptional repressor.
Interferes with normal PML
– Deactivates the tumor-suppression and pro-apoptotic functionsfunctions
– Promoting growth and inhibiting apoptosis
• Dual action gives APL cells a survival advantage and leads to cell proliferation
Variant Translocations
NPM1 ZBTB1ZBTB1
66
NUMA
66
NPM1: Nuclear protein
nucleophosmin
NUMA:
Nuclear mitotic apparatus protein 1
ZBTB16:ZBTB16:
Zinc finger and BTB domain Zinc finger and BTB domain
containing 16containing 16
APL
• Three regions of the PML locus are involved in
the translocation breakpoint cluster region (bcr):
• Intron 6 (bcr1)
• Exon 6 (bcr2)
• Intron 3 (bcr3)
• Whereas RARA breakpoints always occur in
intron 2, which is 17 kb in length.intron 2, which is 17 kb in length.
Cancer Genetics and Cytogenetics 188(2009) 103 107.
Leukemia Research 26 (2002): 439-442
PML/RARA Isoforms
• Long or bcr1• Long or bcr1
• Variant (V or bcr2)
• Short (S or bcr3): POOR OUTCOME.
• MOST OF THESE TRANSCRIPTS
CAN BE DETECTED BY CAN BE DETECTED BY
COMMERCIALLY AVAILABLE RT-
PCR kits.
AML with normal karyotype
• NPM1 and no FLT3 mutations or with • NPM1 and no FLT3 mutations or with
CEBPA (19 p13.1) mutation :
Favorable prognosis
FLT3: 13q12.2
• FLT3 is a member of the class III receptor tyrosine kinase (RTK) family:tyrosine kinase (RTK) family:
24 exons and at least 96 kb.
Expressed in many cell types including hematological stem cells.
• FLT3 mutations ���� constitutive ligand • FLT3 mutations ���� constitutive ligand independent autophosphorylation of receptor � Inhibition of APOPTOSIS & proliferation of leukemic cells.
FLT3: 13q12.2• 20-25% are internal tandem duplication (FLT3/ITD) or FLT3-
LM (length mutation)
(Juxtamembrane domain ) (Juxtamembrane domain )
In 20-25% AML, 5-10 % MDS.
• 7-9% mutations in the second tyrosine kinase domain, mostly point mutations in codon 835 (D835) or deletions of codon 836
In 7-8% of all AML and 3-15% of MDS.In 7-8% of all AML and 3-15% of MDS.
• Inhibition of APOPTOSIS and proliferation of leukemic cells� Unfavorable prognosis, high relapse rate.
AML with MDS related changes
-7, Del (7q) Del(11q)
-5/del(5q) -13/Del(13q)
i(17q) or i(17p)
Del(12p)/t(12p)
Del(9q)
Idic(Xp)
AML with MDS related changes
t(11;16)(q23;p13.3) t(5;17)(q33;q21)t(11;16)(q23;p13.3)
t(3;21)(q26.2;q22.1)
t(1;3)(p36.3;q21.1)
t(5;17)(q33;q21)
t(5;10)(q33;q21)
t(3;5)(q25;q34)
t(5;12)(q33;p12)
Complex karyotypes are seen
in lymphomas
t(8;14)(q24;q32)
t(2;8)(p12;q24)
t(8;22)(q24;q11)
Aqua – centromere on chromosome 8
Red – MYC locus on chromosome 8
Green – IGH locus on chromosome 14
MYC/IGH
MYC/IGH
• B-cell malignant neoplasias. • B-cell malignant neoplasias.
• No hybrid gene but
• Constitutive expression of C-MYC induces
proliferation even in the absence of growth
factorsfactors
t(14;18)(q32;q21)
t(2;18)(p11;q21)
t(18;22)(q21;q11)
• Extra nodal marginal B-cell lymphoma:t(11;18)(q21;q21) API2 (BIRC3) with MALT1
(Fusion protein 5’API2 with 3’MALT1)
• Anaplastic Large B-cell lymphoma: t(2;5)(p23;q35) • Anaplastic Large B-cell lymphoma: t(2;5)(p23;q35) ALK/NPM1
• Follicular lymphoma: t(14;18)(q32;q21) IGH/BCL2Promoter exchange.
The IgH gene enhancer stimulates the expression of The IgH gene enhancer stimulates the expression of BCL2. Upregulates APOPTOSIS. As BCL2 is an apoptosis inhibitor, cell death is delayed.
Gene amplificationGene amplification
• Concurrent FISH analysis • Concurrent FISH analysis
confirmed amplification of
the MYCN gene.
Amplification of MYCN is
found in various tumors, in
particular neuroblastoma;
the level of amplification the level of amplification
increases with tumor
progression.
46,XX,add(1)(p22),add(9)(p22),add(13)(q34),add(14)(q22),a
dd(15)(q26.1),1-16dmin[cp20]
47~49,XY,+r,+1-4mar[cp9]. ish
r(12)(MDM2+),mar(12)(MDM2+)
Well-differentiated liposarcoma
nuc ish(EWSR1x2)( 5’EWSR1 sep
3’EWSR1x1)[290/300]
96.7%
(290/300)
Her-2/neu
• It plays a key role in the regulation of cell growth
• It has been shown to be amplified in human breast, • It has been shown to be amplified in human breast, ovarian & other cancers
• It is a prognostic factor in
STAGE II + breast cancer patients. It is further indicated as an aid to predict disease-free & overall survival in these patients (treated with overall survival in these patients (treated with cyclosphosphamide chemotherapy).
ERBB2 (HER2/neu) FISH: POSITIVE FOR HER-2/neu
AMPLIFICATION
Ratio R/G: 8.3
• A ratio of greater than or equal to 2.2 is • A ratio of greater than or equal to 2.2 is
considered amplified.
• A ratio of less than or equal to 1.8 is
considered not amplified.
• A ratio between 1.8 and 2.2 is considered
"equivocal" and the results must be "equivocal" and the results must be
interpreted with caution.
UROVYSION
• DETECTION of ANEUPLOIDY :
3, 7, 17, loss of p16 (9p21) in urine specimens 3, 7, 17, loss of p16 (9p21) in urine specimens from subjects with transitional cell carcinoma of the bladder.
• The results are intended for use as a non-invasive method for monitoring TUMOR RECURRENCE in conjunction with cytoscopyRECURRENCE in conjunction with cytoscopyin patients previously diagnosed with bladder cancer.
UROVYSION TEST
• Detects chromosomal abnormalities associated
with the development and progression of bladder with the development and progression of bladder
cancer.
• UroVysion in conjunction with cystoscopy
delivers the best balance of sensitivity (100%) and
specificity (94.5%).
• Detects bladder cancer recurrence up to 6 months • Detects bladder cancer recurrence up to 6 months
sooner than current diagnostic methods.
• Early detection of high grade disease is critical to
increased survival.
UroVysion
Bladder Cancer FISH Probe Panel
UroVysion Bladder Cancer FISH
(a) normal cell
(c) homozygous 9p21 loss(b) Trisomy 7
Patient D
• Patient born 2/17/1998• Patient born 2/17/1998
• Chromosomes: 46,XY[20]
• Medulloblastoma
(undifferentiated/classic (undifferentiated/classic
type)(WHO grade IV)
RARA 17q21.1
73%
P53
73%
Microarray analysis overview
• Allow us to identify microduplications,
microdeletions and unbalanced translocations.
Microarray analysis
microdeletions and unbalanced translocations.
• It is a great tool to detect the presence of new
and possibly significant chromosomal
abnormalities in cancer, some of which might
be cryptic at the chromosomal level. be cryptic at the chromosomal level.
We can determine in
a single experiment,
the expression levels
of hundreds or thousands
of genes within a cell
Microarray
analysis
of genes within a cell
by measuring the amount
of mRNA bound to each
site on the array.
With the aid of a computer,
the amount of mRNA the amount of mRNA
bound to the spots on the
microarray is precisely
measured, generating a
profile of gene expression in the cell.
SNP array
• Will allow the very small copy-number • Will allow the very small copy-number
aberrations (CNAs) at high accuracy.
• Detect small deletions (< 1 Mb).
• Detection of CNLOH or a UPD
• Reliable detection of low grade mosaicism.• Reliable detection of low grade mosaicism.
Cancer Genetics and Cytogenetics 2008 Vol 180,
Issue 1: 56-59
• A 62-year-old man with gait and speech disturbances. • A 62-year-old man with gait and speech disturbances.
• Computed tomography and magnetic resonance: MASS.
• Tumor was surgically removed .
• Histopathology: Transitional type of meningioma with partially necrotic foci.
• After ~ 1 year, the patient was readmitted due to seizure and left-side hemiparesis.
• Tumor recurrence was discovered and resected. As of • Tumor recurrence was discovered and resected. As of writing, he had remained disease-free for 7 months. The recurrent tumor was diagnosed as a transitional meningioma with necrosis.
del(1)(p36.33p32.1 dup(6)(p25.3p23)
del(12)(p13.33p11.21 del(6)(q16.2q27)
Monosomy 22
Monosomy 18
Monosomy 22
• Monosomy 22 or deletion 22q : The most common chromosomal abnormality in meningiomas.
alterations in addition to
chromosome 22 losses.
• In contrast, complex meningiomas.
• Deletion 1p : 2nd most frequently deleted chromosome arm after 22q in meningiomas.
• In contrast, complex
karyotypes are seen in
aggressive tumor
behavior.
• Benign meningiomas only rarely harbor structural chromosomal
• Malignant progression
of meningiomas: Losses
on 1p, 9p, 10q, and 14q.
Recommendations
• Appropriate specimen processing depends on the • Appropriate specimen processing depends on the
information that accompanies the sample. Critical
information includes patient demographics,
differential diagnosis, symptoms, and other
laboratory findings.
• For hematological tumors, 2-3 ml of bone marrow • For hematological tumors, 2-3 ml of bone marrow
aspirate collected in sodium heparin is the
specimen of choice.
Recommendations
• When a BM aspirate cannot be obtained
because of marrow fibrosis, a BM trephine because of marrow fibrosis, a BM trephine
biopsy or a peripheral blood (PB) specimen
might be successful.
• For PB specimen to yield information about
clonal chromosomal aberrations, the PB clonal chromosomal aberrations, the PB
white cell count must be abnormal.
• Although one of the oldest methods,
remains a powerful tool for genetic remains a powerful tool for genetic
diagnosis and classification of
hematological malignancies and solid
tumors.
• Molecular cytogenetics (FISH) analysis
targets breakpoints specific for a particular targets breakpoints specific for a particular
disease.
The Role of Cytogenetics
• Cytogenetics now standard of care for leukemia • Cytogenetics now standard of care for leukemia patients
• Implementation of cytogenetic subgroups in WHO classification of tumors of hematopoietic and lymphoid tissues in 2008
• Many of the fusion genes associated with identified translocationsidentified translocations
• Prognosis
• Targets for therapy